BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 30210349)

  • 1. Pharmacokinetic Behavior of Vincristine and Safety Following Intravenous Administration of Vincristine Sulfate Liposome Injection in Chinese Patients With Malignant Lymphoma.
    Yang F; Jiang M; Lu M; Hu P; Wang H; Jiang J
    Front Pharmacol; 2018; 9():991. PubMed ID: 30210349
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetic characteristics of vincristine sulfate liposomes in patients with advanced solid tumors.
    Yan Z; Zhu ZL; Qian ZZ; Hu G; Wang HQ; Liu WH; Cheng G
    Acta Pharmacol Sin; 2012 Jun; 33(6):852-8. PubMed ID: 22669119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of vincristine sulfate liposome injection (VSLI) in adults with acute lymphoblastic leukemia.
    Silverman JA; Reynolds L; Deitcher SR
    J Clin Pharmacol; 2013 Nov; 53(11):1139-45. PubMed ID: 23907766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of free and total vincristine in human plasma after intravenous administration of vincristine sulfate liposome injection using ultra-high performance liquid chromatography tandem mass spectrometry.
    Yang F; Wang H; Liu M; Hu P; Jiang J
    J Chromatogr A; 2013 Feb; 1275():61-9. PubMed ID: 23294995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection.
    Embree L; Gelmon K; Tolcher A; Hudon N; Heggie J; Dedhar C; Logan P; Bally MB; Mayer LD
    Cancer Chemother Pharmacol; 1998; 41(5):347-52. PubMed ID: 9523729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of an UPLC-MS-MS Method for Quantitative Analysis of Vincristine in Human Urine After Intravenous Administration of Vincristine Sulfate Liposome Injection.
    Yang F; Wang H; Hu P; Jiang J
    J Chromatogr Sci; 2015 Jul; 53(6):974-8. PubMed ID: 25520304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma and cerebrospinal fluid pharmacokinetics of vincristine and vincristine sulfate liposomes injection (VSLI, marqibo®) after intravenous administration in Non-human primates.
    Shah NN; Cole DE; Lester-McCully CM; Wayne AS; Warren KE; Widemann BC
    Invest New Drugs; 2016 Feb; 34(1):61-5. PubMed ID: 26661090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and urinary excretion of vincristine sulfate liposomes injection in metastatic melanoma patients.
    Bedikian AY; Vardeleon A; Smith T; Campbell S; Namdari R
    J Clin Pharmacol; 2006 Jul; 46(7):727-37. PubMed ID: 16809798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine.
    Silverman JA; Deitcher SR
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):555-64. PubMed ID: 23212117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas.
    Hagemeister F; Rodriguez MA; Deitcher SR; Younes A; Fayad L; Goy A; Dang NH; Forman A; McLaughlin P; Medeiros LJ; Pro B; Romaguera J; Samaniego F; Silverman JA; Sarris A; Cabanillas F
    Br J Haematol; 2013 Sep; 162(5):631-8. PubMed ID: 23802738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia.
    O'Brien S; Schiller G; Lister J; Damon L; Goldberg S; Aulitzky W; Ben-Yehuda D; Stock W; Coutre S; Douer D; Heffner LT; Larson M; Seiter K; Smith S; Assouline S; Kuriakose P; Maness L; Nagler A; Rowe J; Schaich M; Shpilberg O; Yee K; Schmieder G; Silverman JA; Thomas D; Deitcher SR; Kantarjian H
    J Clin Oncol; 2013 Feb; 31(6):676-83. PubMed ID: 23169518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Vincristine Sulfate Liposome Injection in the Treatment of Adult Acute Lymphocytic Leukemia.
    Douer D
    Oncologist; 2016 Jul; 21(7):840-7. PubMed ID: 27328933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia.
    Thomas DA; Kantarjian HM; Stock W; Heffner LT; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Pierce S; Lu B; Deitcher SR; O'Brien S
    Cancer; 2009 Dec; 115(23):5490-8. PubMed ID: 19708032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of vincristine sulfate liposome injection (Marqibo) and rituximab for patients with relapsed and refractory diffuse large B-Cell lymphoma or mantle cell lymphoma in need of palliative therapy.
    Kaplan LD; Deitcher SR; Silverman JA; Morgan G
    Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):37-42. PubMed ID: 24252360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of liposomal-encapsulated and un-encapsulated vincristine after injection of liposomal vincristine sulfate in beagle dogs.
    Zhong J; Mao W; Shi R; Jiang P; Wang Q; Zhu R; Wang T; Ma Y
    Cancer Chemother Pharmacol; 2014 Mar; 73(3):459-66. PubMed ID: 24362508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-Dose Vincristine Sulfate Liposome Injection, for Advanced, Relapsed, or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in an Adolescent and Young Adult Subgroup of a Phase 2 Clinical Trial.
    Schiller GJ; Damon LE; Coutre SE; Hsu P; Bhat G; Douer D
    J Adolesc Young Adult Oncol; 2018 Oct; 7(5):546-552. PubMed ID: 30239252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vincristine sulfate liposomal injection for acute lymphoblastic leukemia.
    Raj TA; Smith AM; Moore AS
    Int J Nanomedicine; 2013; 8():4361-9. PubMed ID: 24232122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®): Results From a Phase I Study in Children, Adolescents, and Young Adults With Refractory Solid Tumors or Leukemias.
    Shah NN; Merchant MS; Cole DE; Jayaprakash N; Bernstein D; Delbrook C; Richards K; Widemann BC; Wayne AS
    Pediatr Blood Cancer; 2016 Jun; 63(6):997-1005. PubMed ID: 26891067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Release profile of compound liposomes entrapped with vincristine sulfate and mitoxantrone chlorhydric acid in vitro and their distribution in mice].
    Chen T; Hou SX; Wang YY; Zhang WS; Chen DH
    Yao Xue Xue Bao; 2006 Dec; 41(12):1170-5. PubMed ID: 17290615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vincristine Sulfate Liposome Injection with Bendamustine and Rituximab as First-Line Therapy for B-Cell Lymphomas: A Phase I Study.
    Ollila T; Butera J; Egan P; Reagan J; Thomas A; Yakirevich I; MacKinnon K; Margolis J; McMahon J; Rosati V; Olszewski AJ
    Oncologist; 2022 Jul; 27(7):532-e542. PubMed ID: 35641232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.